Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC

Amino, Yoshiaki; Kitazono, Satoru; Uematsu, Shinya; Hasegawa, Toshiyuki; Yoshizawa, Takahiro; Uchibori, Ken; Yanagitani, Noriko; Horiike, Atsushi; Horai, Takeshi; Kondo, Kazuo; Nishio, Makoto

doi:10.1007/s10147-019-01537-4

Cited by 6 publications

(13 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it was helpful in previous cases with specific situations, consistent with the theoretical basis delivered in detail in the Discussion. The PFS in the current case has reached 23 months with an ongoing regimen, which surpassed the 8.4 months of median PFS of the ICI monotherapy for the recurrent cases after definitive chemoradiotherapy [16]. The current case suggested the utility of the ABCP regimen among suitable patients who experienced recurrence after CCRT.…”

Section: Discussionmentioning

confidence: 66%

See 1 more Smart Citation

Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung Cancer after Chemoradiotherapy: Case Report

et al. 2021

View full text Add to dashboard Cite

Chemoimmunotherapy has become the standard of care as the first-line treatment of advanced or recurrent non-small-cell lung cancer (NSCLC). The bevacizumab-containing chemoimmunotherapy regimen is theoretically more effective than a non-bevacizumab-containing regimen via two mechanisms: a superior outcome of bevacizumab-containing chemothrerapy than the standard platinum doublet regimen, and the synergistic effect of bevacizumab with an immune checkpoint inhibitor (ICI). Bevacizumab effectively normalizes vascularization, especially when the vascular bed is damaged by previous treatment. Bevacizumab promotes immunomodulation when used with ICI. We describe a patient with nonsquamous NSCLC who returned 2.5 years after definitive chemoradiotherapy for postoperative locoregional recurrence in the right supraclavicular lymph node. Considering the destroyed vascular bed due to prior chemoradiotherapy, attaining vascular normalization was critical for effective drug delivery. The patient was treated with a bevacizumab-containing chemoimmunotherapy regimen, which resulted in a complete metabolic response. The patient responded well for 23 months and is receiving ongoing treatment. Thus, bevacizumab-containing chemoimmunotherapy could be advantageous in some recurrent cases after chemoradiotherapy.

show abstract

Section: Discussionmentioning

confidence: 66%

“…Regarding the recurrent cases after definitive chemoradiotherapy, a retrospective study of anti-PD-1 therapy demonstrated that the objective response ratio and median PFS of ICI monotherapy were 45.0% and 8.4 months, respectively [16]. This study shows the limited efficacy of ICI monotherapy in recurrent cases after chemoradiotherapy.…”

Section: Discussionmentioning

confidence: 73%

Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung Cancer after Chemoradiotherapy: Case Report

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The twenty-five trials consisted of twenty-four trials non-randomized trials ( 11 , 14 , 29 , 31 – 51 ) and one randomized controlled trial ( 30 ). Thirteen trials were conducted in North America ( 11 , 14 , 29 , 31 , 33 , 34 , 39 , 43 , 45 , 46 , 49 – 51 ), nine in Asia ( 32 , 35 – 38 , 40 – 42 , 44 ), and three in Europe ( 30 , 47 , 48 ). Of the twenty-five studies included, nine were prospective studies ( 14 , 29 , 30 , 39 , 45 , 46 , 48 – 50 ) and sixteen were retrospective studies ( 11 , 31 – 38 , 40 – 44 , 47 , 51 ).…”

Section: Resultsmentioning

confidence: 99%

“…Thirteen trials were conducted in North America ( 11 , 14 , 29 , 31 , 33 , 34 , 39 , 43 , 45 , 46 , 49 – 51 ), nine in Asia ( 32 , 35 – 38 , 40 – 42 , 44 ), and three in Europe ( 30 , 47 , 48 ). Of the twenty-five studies included, nine were prospective studies ( 14 , 29 , 30 , 39 , 45 , 46 , 48 – 50 ) and sixteen were retrospective studies ( 11 , 31 – 38 , 40 – 44 , 47 , 51 ). Two trials utilized conventional RT and stereotactic body radiotherapy (SBRT) ( 46 , 51 ), two focused upon SBRT ( 11 , 50 ) and twenty-one trials used conventional RT ( 14 , 29 – 45 , 47 – 49 ).…”

Section: Resultsmentioning

confidence: 99%

Safety and efficacy of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for non-small cell lung cancer: A systematic review and meta-analysis

Ni²,

Deng³

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

BackgroundIt is now widely accepted that radiotherapy (RT) can provoke a systemic immune response, which gives a strong rationale for the combination of RT and immune checkpoint inhibitors (ICIs). However, RT is a double-edged sword that not only enhances systemic antitumor immune response, but also promotes immunosuppression to some extent. Nevertheless, many aspects regarding the efficacy and safety of this combination therapy remain unknown. Therefore, a systematic review and meta-analysis was performed in order to assess the safety and efficacy of RT/chemoradiotherapy (CRT) and ICI combination therapy for non-small cell lung cancer (NSCLC) patients.MethodsPubMed and several other databases were searched (according to specific criteria) to find relevant studies published prior to the 28th of February 2022.Results3,652 articles were identified for screening and 25 trials containing 1,645 NSCLC patients were identified. For stage II-III NSCLC, the one- and two-year overall survival (OS) was 83.25% (95% confidence interval (CI): 79.42%-86.75%) and 66.16% (95% CI: 62.3%-69.92%), respectively. For stage IV NSCLC, the one- and two-year OS was 50% and 25%. In our study, the pooled rate of grade 3-5 adverse events (AEs) and grade 5 AEs was 30.18% (95% CI: 10.04%-50.33%, I2: 96.7%) and 2.03% (95% CI: 0.03%-4.04%, I2: 36.8%), respectively. Fatigue (50.97%), dyspnea (46.06%), dysphagia (10%-82.5%), leucopenia (47.6%), anaemia (5%-47.6%), cough (40.09%), esophagitis (38.51%), fever (32.5%-38.1%), neutropenia (12.5%-38.1%), alopecia (35%), nausea (30.51%) and pneumonitis (28.53%) were the most common adverse events for the combined treatment. The incidence of cardiotoxicity (0%-5.00%) was low, but it was associated with a high mortality rate (0%-2.56%). Furthermore, the incidence of pneumonitis was 28.53% (95% CI: 19.22%-38.88%, I2: 92.00%), grade ≥ 3 pneumonitis was 5.82% (95% CI: 3.75%-8.32%, I2: 57.90%) and grade 5 was 0%-4.76%.ConclusionThis study suggests that the addition of ICIs to RT/CRT for NSCLC patients may be both safe and feasible. We also summarize details of different RT combinations with ICIs to treat NSCLC. These findings may help guide the design of future trials, the testing of concurrent or sequential combinations for ICIs and RT/CRT could be particularly useful to guide the treatment of NSCLC patients.

show abstract

“…For stage IV NSCLC, adding of SBRT to nivolumab is being tested in a phase 2 RCT (NIVORAD, ACTRN12616000352404). For recurrent NSCLC after CRT, a retrospective study provided an interesting result: patients who had a shorter interval from the CRT to initiation of salvage anti-PD-1 therapy tended to have favorable PFS compared to those who had the longer interval (median, 17 months (95% CI: 0.47–not reached) vs. 4.9 months (95% CI: 1.47–8.43), respectively) [ 109 ]. This might suggest that alterations in tumor characteristics and host immunity after CRT could lead to better outcomes with salvage anti-PD-1 therapy.…”

Section: Combination Of Radiotherapy and Icis For Nsclcmentioning

confidence: 99%

A Promising Treatment Strategy for Lung Cancer: A Combination of Radiotherapy and Immunotherapy

Miyasaka

Sato

Okano

et al. 2021

Cancers

View full text Add to dashboard Cite

Lung cancer is a leading cause of cancer-related deaths worldwide despite advances in treatment. In the past few decades, radiotherapy has achieved outstanding technical advances and is being widely used as a definitive, prophylactic, or palliative treatment of patients with lung cancer. The anti-tumor effects of radiotherapy are considered to result in DNA damage in cancer cells. Moreover, recent evidence has demonstrated another advantage of radiotherapy: the induction of anti-tumor immune responses, which play an essential role in cancer control. In contrast, radiotherapy induces an immunosuppressive response. These conflicting reactions after radiotherapy suggest that maximizing immune response to radiotherapy by combining immunotherapy has potential to achieve more effective anti-tumor response than using each alone. Immune checkpoint molecules, such as cytotoxic T-lymphocyte-associated protein 4, programmed cell death-1/programmed death-ligand 1, and their inhibitors, have attracted significant attention for overcoming the immunosuppressive conditions in patients with cancer. Therefore, the combination of immune checkpoint inhibitors and radiotherapy is promising. Emerging preclinical and clinical studies have demonstrated the rationale for these combination strategies. In this review, we outlined evidence suggesting that combination of radiotherapy, including particle therapy using protons and carbon ions, with immunotherapy in lung cancer treatment could be a promising treatment strategy.

show abstract

Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC

Cited by 6 publications

References 25 publications

Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung Cancer after Chemoradiotherapy: Case Report

Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung Cancer after Chemoradiotherapy: Case Report

Safety and efficacy of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for non-small cell lung cancer: A systematic review and meta-analysis

A Promising Treatment Strategy for Lung Cancer: A Combination of Radiotherapy and Immunotherapy

Contact Info

Product

Resources

About